CA
ACRS icon

Clearstead Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Clearstead Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$2 – 2740
2025
Q3 		$2 Buy
+1
New +$2 ﹤0.01% 3075

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Clearstead Advisors's ACRS Position: Q4 2025 in Review

Clearstead Advisors sold out of Aclaris Therapeutics (ACRS) in Q4 2025, closing a stake of 1 share — an estimated $2 sold.

Clearstead Advisors first reported a position in ACRS in Q3 2025 and held it in 1 quarter. The position peaked at $2 in Q3 2025. 122 funds tracked by Wall St. Rank hold ACRS as of Q4 2025.

  • Clearstead Advisors reported no remaining Aclaris Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 1 Aclaris Therapeutics share in Q4 2025, an estimated $2.
  • Clearstead Advisors first reported a position in Aclaris Therapeutics in Q3 2025 and held it in 1 quarter.
  • Clearstead Advisors's Aclaris Therapeutics position peaked at $2 in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.